epirubicin + etoposide + mitomycin C + tamoxifen

**Epirubicin + etoposide + mitomycin C + tamoxifen** is a four-drug combination regimen comprising the anthracycline **epirubicin** (a topoisomerase II inhibitor that intercalates DNA to prevent replication and transcription), the topoisomerase II inhibitor **etoposide** (which stabilizes DNA-topoisomerase II cleavage complexes to induce double-strand breaks primarily in S/G2 phases), the DNA cross-linking agent **mitomycin C** (an alkylating agent that causes interstrand crosslinks), and the selective estrogen receptor modulator **tamoxifen** (an antagonist that blocks estrogen signaling). This multi-modal chemotherapy plus endocrine therapy targets rapidly proliferating cancer cells through DNA damage, replication inhibition, and hormone deprivation, primarily used in breast cancer management, leveraging synergistic cytotoxicity while balancing overlapping toxicities like myelosuppression and cardiotoxicity.